| AMPLY DiscoveryCompanies · also on Labs | Queen's University Belfast spin-out that uses its own AI model to cut the cost of discovering new drugs.Profile- Founded
- Not stated (spun out of Queen's University Belfast; "over 10 years of research")
- Founders
- Ben Thomas — co-founder, CEO and Chief Architect; Dermot Tierney — co-founder; Chris Creevey — co-founder
- Chief executive
- Ben Thomas
- Hq
- Not stated (origin Belfast, Northern Ireland; HQ not stated in source); other_offices: not stated
- What it does
- AMPLY Discovery searches genetic sequencing data with AI to find natural defence molecules and turn them into candidate biologic drugs, then makes them for lab testing. Its programmes are at the preclinical stage. It is a spin-out of the Creevey Lab at Queen's University Belfast.
- Research focus
- AI plus next-generation sequencing and synthetic biology to find biologic drugs; "Evolution has spent billions of years perfecting natural defence mechanisms".
- Models and products
- AMPLYfolioAI — drug discovery platform — named May 2025
- Rounds found
- Sep 2022 — £900,000 (already DEAL-LB-036); Feb 2024 — Innovate UK £1.4m (already DEAL-LAB-2014); 1 May 2025 — seed — $1.75m — Twin Path Ventures — Venture Science, Co-Fund NI, British Business Bank, QUBIS (already DEAL-LAB-2013)
- Status now
- Not stated (no source after May 2025 opened)
Labs Round 8 deep profile (31 Oct 2026), as the researchers wrote it; confidence: one source. Sources - tech.eu/2025/05/01/queens-university-spin-off-am
| Belfast (BT7 1NF) | Companies House · uktech.news/medtech/amply-ai-drug-grant-20240212 · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. · tech.eu/2025/05/01/queens-university-spin-off-am | verified |
| AntiverseCompanies · also on Labs | Cardiff company that uses AI to design antibody drugs against targets that are hard to reach with existing methods.Profile- Founders
- Murat Tunaboylu — co-founder and CEO; Ben Holland — co-founder and CTO
- Chief executive
- Murat Tunaboylu
- Chief scientist or research lead
- Ben Holland — CTO; Gherici Hassaine — Director of Antibody Discovery
- Other leaders
- Michelle Mighdoll — VP Corporate and Business Development; Huw Whyment — Head of Operations; Thane Kreiner — Board Chair; Charles Kunsch — non-executive director
- Hq
- Cardiff (Wales); other_offices: Boston, USA; Prague, Czechia (Outside the UK)
- What it does
- Antiverse designs antibodies with in-house AI and tests them in its own lab, focusing on hard drug targets such as GPCRs (cell-surface receptors). Its "lab in a loop" feeds lab results back into the AI models. It works with pharma companies and foundations.
- Research focus
- "We pair in-house AI with … lab science to design the next generation of GPCR therapeutics."
- Models and products
- Antiverse Platform — AI antibody and nanobody design (design, function, developability, learn layers) with native-membrane screening — not stated; AntiConf — confidence metric for predicted antibody–antigen complexes — 28 Mar 2026; UDIZ-007 — anti-PD-1 antibody (preprint) — 15 Jul 2026
- Customers or partners named
- Cystic Fibrosis Foundation — antibodies against CFTR — 10 Mar 2026 — https://www.antiverse.io/news; Nxera Pharma — GPCR antibody collaboration using generative AI — on or before 28 Dec 2024 — https://www.antiverse.io/news; GlobalBio, Inc. — extended antibody cancer therapeutics collaboration — 16 Oct 2023 — https://www.antiverse.io/news
- Selected papers
- Advances in Therapeutic Antibody Discovery and Development Targeting G Protein-Coupled Receptors — venue not stated — 20 Jan 2026 — https://www.antiverse.io/platform; Confidence scoring for deep learning-predicted antibody–antigen complexes: AntiConf as a precision-driven metric — venue not stated — 28 Mar 2026 — https://www.antiverse.io/platform; Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1 — venue not stated — 25 Nov 2025 — https://www.antiverse.io/platform; Non-Clinical Evaluation of the Anti-PD-1 Antibody UDIZ-007 — preprint — 15 Jul 2026 — https://www.antiverse.io/platform
- Funding total as published
- more than $20m — as of 3 Mar 2026 — https://tech.eu/2026/03/03/antiverse-secures-93m-series-a-for-ai-antibody-platform/
- Rounds found
- 18 Mar 2021 — seed — £1.4m — angel syndicate led by Ed Parkinson (already DEAL-LAB-4022); 3 Mar 2026 — Series A — $9.3m — Soulmates Ventures — Innovation Investment Capital, DOMiNO Ventures; existing DBW, Kadmos Capital, i&i Biotech Fund (already DEAL-INV-015 / DEAL-SU-HLT-012)
- Status now
- Trading; closed a $9.3m Series A in March 2026 and began a research agreement with the Cystic Fibrosis Foundation.
Labs Round 8 deep profile (31 Oct 2026), as the researchers wrote it; confidence: verified (Series A: company news page plus trade); total raised one source. Sources - antiverse.io/about
- antiverse.io/news
- tech.eu/2026/03/03/antiverse-secures-93m-series-
Models and products (2)- AntiConf (antibody-antigen confidence score) 2026-03-28 released (paper)Antiverse method that scores how far to trust AI-predicted structures of antibodies bound to their targets.
- Antiverse Platform — (date not stated) live (in-house and partnered discovery)Antiverse's AI system for designing antibodies against hard drug targets such as GPCRs and ion channels.
| Cardiff (CF24 4HQ) | Companies House · uktech.news/ai/welsh-biotech-raises-7m-for-ai-de · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. · uktech.news/featured/wales-antibody-drug-discove | verified |
| BenevolentAICompanies | London company that uses AI to find drug targets and develop its own medicines; taken private and delisted from Amsterdam in March 2025. merged | 4-8 Maple Street, London (W1T 5HD) | Companies House · businesswire.com/news/home/20250312584164/en · find-and-update.company-information.service.gov. · sifted.eu/articles/ai-drug-discovery-startups | verified |
| Big Picture BioCompanies | Biotech start-up using AI to design combinations of cancer drugs. | Ingatestone (registered office, CM4 9DW ) | Companies House · tech.eu/2026/09/21/european-tech-weekly-recap-ov · find-and-update.company-information.service.gov. | verified |
| BiorelateCompanies | Manchester company whose Galactic AI platform reads biomedical literature and data to help drug developers. | Manchester (M15 6SE) | Companies House · uktech.news/medtech/biorelate-series-a-20221129 · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. | verified |
| CausalyCompanies | London company whose AI platform reads biomedical research to help drug companies speed up drug discovery. | London | Companies House · uktech.news/medtech/ai-biotech-research-platform · find-and-update.company-information.service.gov. | verified |
| CHARM TherapeuticsCompanies | Structure-led drug discovery company using AI to find cancer medicines. | London (N1C 4AG) | Companies House · businessweekly.co.uk/posts/cambridge-life-scienc · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. | verified |
| ExscientiaCompanies | Oxford company that used AI to design small-molecule drugs; bought by US firm Recursion in November 2024. acquired | Oxford | Companies House · find-and-update.company-information.service.gov. · sifted.eu/articles/ai-drug-discovery-startups · ir.recursion.com/news-releases/news-release-deta · find-and-update.company-information.service.gov. | verified |
| HealxCompanies · also on Labs | Cambridge company that uses AI to find treatments for rare diseases and runs its own clinical trials. | Cambridge (CB2 1LA) | Companies House · uktech.news/medtech/healx-series-c-round-2024080 · find-and-update.company-information.service.gov. · sifted.eu/articles/ai-drug-discovery-startups · find-and-update.company-information.service.gov. | verified |
| Ignota LabsCompanies | Cambridge company that uses AI to work out why promising drugs failed on safety grounds, and then tries to rescue them. | Cambridge (CB4 0WS) | Companies House · businessweekly.co.uk/posts/honour-for-cso-mainta · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. | verified |
| iLoF (Intelligent Lab on Fiber)Companies | Oxford and Porto company building an AI library of disease biomarkers to help drug firms pick patients for trials. | Oxford | Companies House · uktech.news/medtech/ilof-funding-20220728 · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. | verified |
| Kiin BioCompanies | London start-up building a generative-AI 'virtual scientist' to speed up drug discovery. | London | Companies House · uktech.news/medtech/ai-drug-discovery-startup-ki · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. | verified |
| KuanoCompanies · also on Labs | Cambridge start-up combining AI and quantum simulation of enzymes to design drugs.Profile- Legal name
- Kuano Ltd (site footer)
- Founded
- 2020
- Founders
- Vid Stojevic — CEO and co-founder; David Wright — CTO and co-founder; Parminder Ruprah — Head of Chemistry and co-founder; Jarryl D'Oyley — Project Manager and co-founder
- Chief executive
- Vid Stojevic
- Chief scientist or research lead
- David Wright — CTO
- Other leaders
- Antonio Benedetti — Executive Chairman (from 13 Jul 2022); Georg Schusteritsch — Senior Quantum Scientist; Will Gerrard — Platform Development Team Lead; Andy Mulvaney — non-executive director (from 24 May 2021); Ted Witek — board member (from 20 Feb 2024); Sunil Shah — non-executive director
- Hq
- Hauxton, Cambridge (England: East of England), Mill SciTech Park; other_offices: not stated
- What it does
- Kuano designs drug candidates for enzyme targets by combining quantum-chemistry simulation with AI design. Its platform runs automated quantum and molecular simulations, then uses AI to propose and optimise molecules, from finding hits to optimising leads.
- Research focus
- Quantum chemistry, molecular simulation and molecular design; transition-state drug design for enzyme targets.
- Models and products
- Quantum Lens — simulation and modelling platform — not stated; Kuano design engine — AI plus physics-based molecular design — not stated; agent-supported platform — demonstrated in Singapore — 1 Sep 2026
- Customers or partners named
- CROZ — engineering partner — not stated — https://www.kuano.ai/about/; University of Bristol (Mulholland group) — IRAP research collaboration — 13 Jun 2025 — https://www.kuano.ai/news; Alzheimer's Research UK UCL Drug Discovery Institute — research collaboration — 24 Jun 2021 — https://www.kuano.ai/news/older/; UCL and NQCC — Innovate UK quantum computing feasibility study 2023–25 — https://www.kuano.ai/case-studies
- Selected papers
- Molecular insight into IRAP activity and inhibition — Journal of Chemical Information and Modeling — 2025 — https://doi.org/10.1021/acs.jcim.5c00869; What is the future role of quantum computation in drug discovery? — Emerging Topics in Life Sciences — 2025 — https://pmc.ncbi.nlm.nih.gov/articles/PMC12599230/; Parallel quantum simulation of large systems on small NISQ computers — npj Quantum Information — 2021 — https://arxiv.org/abs/2003.12087
- Funding total as published
- £2.8m — as of 12 Sep 2023 — https://www.kuano.ai/news/we-are-delighted-to-announce-the-close-of-our-18m-seed-funding-round-to-accelerate-our-quantum-based-drug-discovery
- Rounds found
- 25 Feb 2021 — pre-seed — amount not stated — o2h human health EIS Fund (lead of consortium) — not stated (new DEAL-LAB-16021); Jul–Aug 2021 — seed — £1m — ACF Investors, o2h Ventures and angels (already DEAL-LAB-4015); 12 Sep 2023 — seed — £1.8m — Mercia Ventures — ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory, angels (already DEAL-LAB-2015 / DEAL-SU-HLT-051)
- Awards and programmes
- Innovate UK grant — 25 Jun 2020; Creative Destruction Lab Quantum stream graduate — 1 Jul 2021; Innovate UK £540,000 cancer-drug project — 9 Jan 2023; Cofinitive #21toWatch 2024 — 13 Mar 2024
- Status now
- Trading; showed an agent-supported platform in Singapore and attended Life Sciences Week in September 2026.
Labs Round 8 deep profile (31 Oct 2026), as the researchers wrote it; confidence: one source. Sources - kuano.ai/news/we-are-delighted-to-announce-the-c
- kuano.ai/news/older/
- kuano.ai/about/
| Cambridge | Companies House · uktech.news/medtech/kuano-seed-20230913 · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. · tech.eu/2023/09/12/kuano-raises1-8m-for-drug-dis | verified |
| LabGeniusCompanies · also on Labs | London company that uses machine learning and robotic experiments to design antibody drugs.Profile- Founders
- Not stated (founders not named in sources opened)
- Chief executive
- James Field — from at least Nov 2017
- Other leaders
- Irina Haivas (Atomico) — board member from Oct 2020
- Hq
- London (England: London); other_offices: not stated
- What it does
- LabGenius discovers antibody drugs using EVA, a robotic lab platform guided by machine learning that designs its own experiments, runs them and learns from the results. It focuses on multispecific antibodies that hit diseased cells while sparing healthy cells with the same markers.
- Research focus
- Machine-learning-driven antibody engineering; multi-objective Bayesian optimisation; on-target, off-tumour toxicity.
- Models and products
- EVA — robotic, machine-learning-driven discovery platform — named 2017; wholly-owned multispecific antibody pipeline — not stated
- Funding total as published
- £58m — as of 22 May 2024 — https://tech.eu/2024/05/22/labgenius-secures-ps35m-series-b-funding-for-therapeutic-antibody-discovery/
- Rounds found
- 24 Nov 2017 — seed — $3.66m — Kindred Capital and Acequia Capital — Berggruen Holdings, Backed VC, Beast Ventures, System.One, Charlie Songhurst, Tom McInerney (new DEAL-LAB-16001); Oct 2019 — Series A first close — $10m (already DEAL-LA-035); 29 Oct 2020 — Series A extension — $15m (round total $25m) — Atomico — Lux Capital, Obvious Ventures, Kindred Capital, Inovia Capital (new DEAL-LAB-16002); 22 May 2024 — Series B — £35m — M Ventures — Octopus Ventures, LG Corp; existing Atomico, Kindred, Lux, Obvious (already DEAL-LAB-2019 / DEAL-SU-HLT-037)
- Status now
- Not stated (no source from the last 12 months could be opened; labgenius.com blocks automated reading)
Labs Round 8 deep profile (31 Oct 2026), as the researchers wrote it; confidence: one source (trade only). Sources - tech.eu/2024/05/22/labgenius-secures-ps35m-serie
- tech.eu/2020/10/29/labgenius-series-a/
- tech.eu/2017/11/24/labgenius-funding/
Models and products (1)- EVA drug discovery platform (LabGenius) 2024-05-21 liveLabGenius' machine-learning platform that designs antibody experiments, runs them and learns from the results.
| London | Companies House · uktech.news/medtech/labgenius-drug-discovery-ser · find-and-update.company-information.service.gov. · tech.eu/2024/05/22/labgenius-secures-ps35m-serie · tech.eu/2020/10/29/labgenius-series-a/ | verified |
| Magnitude BiosciencesCompanies | Durham University spin-out that tests drug candidates on tiny worms, using imaging, machine learning and robotics to read the results. | NETPark, Sedgefield (TS21 3FD) | Companies House · uktech.news/funding/magnitude-biosciences-raises · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. | verified |
| OutSeeCompanies | University of Cambridge spin-out that uses AI to predict disease from a single genome to find new drug targets. | Cambridge | Companies House · uktech.news/medtech/outsee-raises-1-8m-seed-fund · find-and-update.company-information.service.gov. · uktech.news/medtech/outsee-raises-1-8m-seed-fund · find-and-update.company-information.service.gov. | verified |
| PeptoneCompanies · also on Labs | Protein-engineering software company that uses AI and physics-based computing to help design medicines.Models and products (1)- PepTron-o (Peptone) 2025-06-12 announcedPeptone and NVIDIA model that predicts the shifting shapes of "disordered" proteins.
| (registered office NG18 1RR) | Companies House · uktech.news/news/uk-biotech-peptone-funding-for- · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. · peptone.io/ | verified |
| PercepticCompanies | Single AI system that joins up asset scouting, scientific evaluation and clinical data for drug discovery and development decisions. | London (N3 1XW ) | Companies House · uktech.news/ai/perceptic-raises-9m-to-boost-ai-s · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. | verified |
| Relation TherapeuticsCompanies | London biotech that uses genomics and machine learning to find and develop new medicines. | Regent's Place, Euston Road, London | Companies House · uktech.news/medtech/relation-doubles-london-foot · find-and-update.company-information.service.gov. | verified |
| Shift BioscienceCompanies · also on Labs | Cambridge company using generative AI to find genes that could make ageing cells young again, as a route to treating age-related disease.Profile- Founded
- May 2017 (company timeline)
- Founders
- Daniel Ives — founder and CEO; Brendan Swain — co-founder and CSO
- Chief executive
- Daniel Ives — from 2017
- Chief scientist or research lead
- Brendan Swain — CSO
- Other leaders
- Laurence Reid — non-executive director (from 11 Mar 2025); Jill Reckless — Translation Advisor (from 11 Mar 2025)
- Hq
- Cambridge (England: East of England), at the Gurdon Institute via the Frame Shift bio-incubator; other_offices: not stated (a North American facilities release exists but could not be opened)
- What it does
- Shift Bioscience uses AI models of cells (a "virtual cell") and a biological ageing clock to find genes that can safely make old cells behave like younger ones, aiming at medicines for age-related disease. In 2025 it reported a single-gene target, SB000.
- Research focus
- Cell rejuvenation; generative AI cell simulation combined with a high-throughput ageing clock.
- Models and products
- AI-powered virtual cell platform — gene-target discovery for rejuvenation — not stated; SB000 — single-gene rejuvenation target — 9 Jun 2025
- Selected papers
- SB000 preprint (title not captured) — bioRxiv — Jun 2025 — https://www.biorxiv.org/content/10.1101/2025.06.05.657370v1
- Funding total as published
- £14m — as of Oct 2024 — https://tech.eu/2024/10/15/shift-bioscience-raises-ps125m-to-advance-ai-driven-ageing-research/
- Rounds found
- Jul 2017 — initial seed — amount not stated — not stated — not stated; 15–16 Oct 2024 — seed — £12.5m — BGF — F-Prime Capital, Kindred Capital, Jonathan Milner (already DEAL-SU-HLT-034 as $16m)
- Awards and programmes
- Accelerate@Babraham start-up competition winner — May 2019
- Status now
- Trading; working on its SB000 rejuvenation target after adding a translation adviser and non-executive director in March 2025.
Labs Round 8 deep profile (31 Oct 2026), as the researchers wrote it; confidence: one source. Sources - tech.eu/2024/10/15/shift-bioscience-raises-ps125
- shiftbioscience.com/news/shift-bioscience-identi
- businesswire.com/news/home/20250311855995/en/Shi
- shiftbioscience.com/news/
Models and products (1)- Shift Bioscience virtual cell and cell-ageing clock platform (SB000 discovery) 2025-06-09 (first named target announced) live (in-house discovery platform)Shift Bioscience's AI "virtual cell" and ageing-clock tools, used to find single genes that may make old cells behave younger.
| Cambridge | Companies House · uktech.news/ai/shift-bioscience-gen-ai-reverse-a · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. · financialcontent.com/article/bizwire-2026-10-5-s | verified |
| Ternary TherapeuticsCompanies · also on Labs | London start-up building an AI platform to design 'molecular glue' medicines. | London (NW1 3BF) | Companies House · uktech.news/medtech/biotech-building-molecular-g · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. | verified |